Page last updated: 2024-09-04

carbapenems and canertinib dihydrochloride

carbapenems has been researched along with canertinib dihydrochloride in 1 studies

Compound Research Comparison

Studies
(carbapenems)
Trials
(carbapenems)
Recent Studies (post-2010)
(carbapenems)
Studies
(canertinib dihydrochloride)
Trials
(canertinib dihydrochloride)
Recent Studies (post-2010) (canertinib dihydrochloride)
7,3551475,27731136

Protein Interaction Comparison

ProteinTaxonomycarbapenems (IC50)canertinib dihydrochloride (IC50)
Epidermal growth factor receptorHomo sapiens (human)0.0036
Receptor tyrosine-protein kinase erbB-2Homo sapiens (human)0.0132
Receptor tyrosine-protein kinase erbB-4Homo sapiens (human)0.029

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Behnke, M; Dinkelacker, A; Eisenbeis, S; Falgenhauer, J; Gastmeier, P; Häcker, G; Herold, S; Imirzalioglu, C; Jazmati, N; Käding, N; Kern, WV; Kramme, E; Mischnik, A; Peter, S; Piepenbrock, E; Rohde, AM; Rupp, J; Schneider, C; Schwab, F; Seifert, H; Steib-Bauert, M; Tacconelli, E; Trauth, J; Vehreschild, MJGT; Walker, SV1

Other Studies

1 other study(ies) available for carbapenems and canertinib dihydrochloride

ArticleYear
Association of ward-level antibiotic consumption with healthcare-associated Clostridioides difficile infections: an ecological study in five German university hospitals, 2017-2019.
    The Journal of antimicrobial chemotherapy, 2023, 09-05, Volume: 78, Issue:9

    Topics: Anti-Bacterial Agents; Carbapenems; Clostridioides difficile; Clostridium Infections; Cross Infection; Hospitals, University; Humans; Incidence; Retrospective Studies

2023